Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs BHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 44.1 HOLD), While BHC Leads 5–1 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: AVDL 1 – 5 BHC Matrix Metrics: AVDL 6 – 4 BHC

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Bausch Health Companies Inc (BHC) on higher Unified Composite conviction (62.9/100 BUY vs. 44.1/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality), while BHC wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus BHC at $8.22 (1.9x Forward P/E, 27.2% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. BHC 44.1/100 HOLD) and 0.14β · 2% Vol risk profile, whereas BHC leads top-line expansion (+9.7% YoY revenue growth, 0.01x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs BHC
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
BHC NYSE
Bausch Health Companies Inc
Pharmaceutical Preparations
$8.22
-3.97% 1D
Market Cap $3.2B
TTM Revenue $11.1B
Forward P/E 1.9x
Beta / 30D Vol 0.96β · 111% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 32.0 Fund 47.0 Flow 70.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 59
RSI-14: 58.5 · SMA20: $8.07 · SMA50: $6.80

6-Pillar Scorecard Institutional Category Breakdown (AVDL 1 – 5 BHC)

Columns: Metric · AVDL · BHC
1. Valuation Multiples BHC
Forward P/E 28.8x 1.9x
Trailing P/E 16.8x 2.0x
PEG Ratio 0.07x 0.01x
EV / Revenue 8.5x 0.3x
2. Growth & Scale BHC
Revenue Growth (YoY) +54.9% +9.7%
Earnings Growth (YoY) +0.0% +139.6%
TTM Revenue (USD) $249M $11.1B
Market Cap $2.1B $3.2B
3. Profitability & Quality AVDL
Gross Margin 94.9% 72.6%
Operating Margin 2.5% 27.2%
Net Profit Margin -0.1% -7.6%
Return on Equity (ROE) -0.3% -11040.0%
4. Balance Sheet & Cash Flow BHC
Cash Generation (TTM) $2.7M EBITDA $1.83B
Cash Flow Margin 1.1% EBITDA Mgn 16.4%
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE -11040.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHC
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 2.4% (<1st %ile) 471.5% (100th %ile)
Put/Call OI Skew N/A 0.13x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat BHC
OpEx & R&D Intensity N/A 45.4% of Rev ($5.05B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (6) vs BHC (4)
Institutional Metric AVDL BHC Criterion Row Edge
Market Capitalization
Scale
$2.1B $3.2B Larger Scale BHC
Trailing P/E Ratio
Valuation
16.8x 2.0x Lower Multiple BHC
Forward P/E Ratio
Valuation
28.8x 1.9x Lower Multiple BHC
Revenue Growth (YoY)
Growth
+54.9% +9.7% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 27.2% Higher Margin BHC
Net Profit Margin
Profitability
-0.1% -7.6% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
-0.3% -11040.0% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 83% ($4–$9) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.96β · 111% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 44.1 / 100 (HOLD) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $11.1B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 72.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev 0.01x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $1.83B (-11040.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +19.48 pp
AVDL: +0.65% · BHC: -18.83%
3M Horizon BHC +6.82 pp
AVDL: -6.32% · BHC: +0.5%
6M Horizon BHC +6.82 pp
AVDL: -6.32% · BHC: +0.5%
1Y Horizon BHC +6.82 pp
AVDL: -6.32% · BHC: +0.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs BHC. Trailing 12-month operating profitability (AVDL 2.5% vs BHC 27.2%) and valuation multiples (AVDL 28.8x vs BHC 1.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
BHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11.1B
Gross Margin72.6%
Op. Margin27.2%
ROE / Fwd P/E-11040.0% · 1.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHC BREAKOUT
78d in phase · OBV ACCUMULATION
Current IV 471.5%
IV Percentile 100th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHC Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.2B market capitalization and 27.2% operating margin.
OpEx & R&D Reinvestment 45.4% of Rev ($5.05B)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs BHC Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Bausch Health Companies Inc (BHC) on higher Unified Composite conviction (62.9/100 BUY vs. 44.1/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality), while BHC wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus BHC at $8.22 (1.9x Forward P/E, 27.2% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. BHC 44.1/100 HOLD) and 0.14β · 2% Vol risk profile, whereas BHC leads top-line expansion (+9.7% YoY revenue growth, 0.01x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

BHC leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with BHC at +9.7% YoY revenue growth and +139.6% YoY earnings growth on $11.1B TTM revenue (72.6% gross margin, 27.2% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $11.1B for BHC. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 45.4% of Rev ($5.05B) (0 disclosures) for BHC.

BHC screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas BHC trades at 1.9x Forward P/E, 2.0x Trailing P/E, 0.01x PEG, and 0.3x EV/Revenue (16.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus BHC (-11040.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, BHC carries 471.5% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.96β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.